What is the best medication treatment strategy for chronic pain in a 58-year-old woman who is taking bupropion and escitalopram for depression and anxiety and cannot tolerate duloxetine?

Best Medication Treatment Strategy for Chronic Pain

For this 58-year-old woman already on bupropion and escitalopram who cannot tolerate duloxetine, I recommend initiating gabapentin or pregabalin as first-line therapy for chronic pain, starting with gabapentin 100-300 mg nightly and titrating slowly to 900-3600 mg daily in divided doses. 1

Rationale for This Approach

The patient is already taking bupropion, which has documented analgesic properties at doses of 150-450 mg daily 2. However, bupropion's evidence for chronic pain is limited and extrapolated primarily from cancer pain guidelines 2. While she's already on this medication for depression, don't expect it to provide substantial pain relief—the evidence is weak compared to other options.

Since duloxetine (the preferred SNRI for chronic pain) is not tolerated, and she's already on escitalopram (an SSRI with minimal analgesic properties), the most evidence-based next step is adding a gabapentinoid 1.

Specific Medication Recommendations

First-Line: Gabapentinoids

Gabapentin:

• Start: 100-300 mg at bedtime
• Titrate: Increase by 50-100% every few days
• Target: 900-3600 mg daily in 2-3 divided doses
• Use slower titration given her age (58 years) 2
• Requires dose adjustment if renal insufficiency present 2

Pregabalin (alternative):

• Start: 50 mg three times daily
• Target: 100 mg three times daily (up to 600 mg/day maximum)
• More efficiently absorbed than gabapentin 2
• Also requires slower titration at age 58 2
• Requires renal dose adjustment 2

Second-Line: Tricyclic Antidepressants

If gabapentinoids fail or are not tolerated, add a secondary amine TCA (better tolerated than tertiary amines) 1:

Nortriptyline or Desipramine:

• Start: 10-25 mg nightly
• Titrate: Every 3-5 days
• Target: 50-150 mg nightly
• Preferred over amitriptyline/imipramine due to fewer anticholinergic effects 2, 1
• Obtain screening ECG given age >40 years 1
• Limit to <100 mg/day when possible 1

Third-Line: Venlafaxine

If both gabapentinoids and TCAs fail:

Venlafaxine:

• Start: 50-75 mg daily
• Target: 75-225 mg daily 2, 1
• This is the only other SNRI with pain evidence besides duloxetine 1

Adjunctive Topical Therapy

Regardless of systemic medication chosen, add topical agents if pain is localized 3, 1:

• Lidocaine 5% patch: Apply daily to painful site (minimal systemic absorption) 2
• Diclofenac gel: Apply 3 times daily to localized areas 2

Critical Considerations

Drug Interactions

Bupropion inhibits CYP2D6 4, which can increase concentrations of:

• TCAs (nortriptyline, desipramine, imipramine)
• Venlafaxine
• Other antidepressants

If adding a TCA or venlafaxine, start at the lower end of the dosing range and monitor closely for side effects 4. Consider dose reduction of the added medication if needed.

What NOT to Do

• Do not add another SSRI—escitalopram has minimal analgesic properties 1
• Do not use skeletal muscle relaxants for chronic pain—insufficient evidence 5
• Do not use benzodiazepines—minimal pain evidence and significant risks 5
• Avoid increasing bupropion dose solely for pain—limited evidence and may worsen anxiety 6

Monitoring Strategy

Set realistic expectations upfront 2:

• Emphasize trial-and-error nature of treatment
• Analgesic doses may be lower than antidepressant doses
• Onset of pain relief typically earlier than mood effects 2
• Titrate until: analgesic effect achieved, side effects unmanageable, or maximum dose reached 2

If inadequate response after adequate trial (6-8 weeks at target dose) 1:

1. Switch to alternative first-line medication
2. Or add second first-line medication (e.g., gabapentin + TCA)
3. Consider pain specialist referral if multiple trials fail 1

Special Consideration for Anxiety

Bupropion can be anxiogenic, particularly at higher doses 6. If her anxiety worsens:

• Ensure bupropion dose is not excessive
• Gabapentinoids may help with anxiety symptoms
• TCAs (especially nortriptyline) can address comorbid anxiety and insomnia 2

Evidence Quality Note

The strongest evidence for chronic pain management comes from 2020 geriatric guidelines recommending duloxetine and gabapentinoids as first-line 3, and 2010 neuropathic pain guidelines establishing TCAs, SNRIs, and gabapentinoids as first-line therapies 1. The 2024 network meta-analysis confirms duloxetine as the most effective antidepressant for chronic pain 7, but since she cannot tolerate it, gabapentinoids become the evidence-based choice.